Divis Laboratories Ltd

- No specific mention of current or future fundraising through debt or equity was disclosed in the transcript. - The company discussed ongoing and planned capital expenditures, including ₹1,000 crores assumed for the current year, mainly towards the Kakinada Greenfield project and other expansions. - Management stated CAPEX is ongoing and will be based on project finalizations but did not indicate any planned fundraising. - Cash on hand was reported at ₹3,602 crores as of September 30, 2024, indicating strong liquidity. - Any substantial future CAPEX requiring additional funding would be communicated as needed. - No direct references were made regarding plans for raising funds via debt or equity during this earnings call.

- Divi’s Laboratories is undertaking a significant Greenfield expansion at Unit-III, a 200-acre project. - Phase-wise production at Unit-III is expected to commence from December 2024. - Capital work-in-progress as of September 30, 2024, stands at ₹1,316 crores, with the Kakinada project accounting for ₹1,006 crores. - Total amount spent on the Kakinada project till September 30, 2024 is ₹1,181 crores. - Capitalized assets during the current quarter were ₹64 crores and ₹124 crores during the half year. - The company anticipates CAPEX of approximately ₹1,000 crores including Kakinada for the current year, pushing total CAPEX to around ₹1,600 crores. - Future CAPEX will depend on finalized Custom Synthesis projects and expansion plans, with ongoing investments expected but possibly lower than the current year unless new opportunities arise. - Divi’s is also expanding its Solid Phase Peptide Synthesis facilities and plans to scale up continuous flow chemistry technology to commercial scale in the next 1-2 years.

- Existing generic products are stable with volume growth. - Sartan business is growing steadily. - Future generics launching from 2026 to 2029, currently in customer qualification phases, expected to contribute significantly. - Custom synthesis projects focused on GLP-1 peptides show huge opportunities, with many molecules in phase II/III trials. - Contrast media volumes expected to grow 20-30% year-on-year. - Increased number of RFPs and onsite customer visits indicate growing demand in custom synthesis. - Advanced shipments and extended supply chain measures support volume growth despite logistical challenges. - Volume-based growth in generic products is double-digit, contributing to 49% of total revenue. - Unit-III expansion (starting December 2024) will support volume ramp-up over time. - Pricing pressure in generics expected to stabilize within 6-12 months, supporting revenue growth.

- Divi’s Laboratories expects revenue growth driven by six growth engines including stable existing generics, steadily growing Sartan business, and launch of future generics from 2026 through 2029. - New generics currently in various qualification stages are expected to start contributing revenues from 2026 onward. - Custom synthesis, especially in GLP-1 peptides and other phase II/III molecules, shows strong demand and opportunities. - Contrast media segment and expansion in solid phase peptide synthesis capacities are projected to support volume and revenue growth. - Greenfield expansion at Unit-III starting production from December 2024 will add capacity; EBITDA breakeven is expected to be gradual as commercial supplies stabilize. - Despite generic pricing pressure, volume growth and market share gains in generics support earnings. - The company anticipates margin normalization and sustainable double-digit growth over full fiscal years. - CAPEX remains high (~₹1,600 crores current year), reflecting investments for future growth, with further additions aligned to new projects and expansions.

- Divi’s Laboratories receives numerous RFQs (Requests for Quotations) from customers at various stages: phase-I, phase-II, phase-III, or ready to launch. - Conversion of RFQs into business depends on the molecule's development stage, regulatory approvals, and customer strategy. - The timeline for converting RFQs to business varies widely; some projects may move slowly due to regulatory or development issues. - There is a ₹650 to ₹700 crore dedicated project expected to become an opportunity by FY'27, but details remain confidential. - The company is actively qualifying products for future generic supply starting mostly from 2026 onwards. - Expansion and investment decisions continue based on finalized custom synthesis projects and customer demand. - Overall, the order pipeline is strong but subject to confidentiality and regulatory factors, making precise quantification difficult.